CD274 and hepatocellular carcinoma: Here, we characterize long-term survival outcomes and clinical-genomic features of complete responders to immunotherapy (defined as a complete response according to Response Evaluation Criteria in Solid Tumors [RECIST] or modified RECIST) among patients with HCC from the IMbrave150 trial and a large multicenter cohort of patients treated with anti–programmed cell death 1 ligand 1 (PD-1/L1) therapies in the first-line setting.5